Loading
Life sciences · Journal article
Frontiers in Psychiatry · August 12, 2026
Raises a question worth testing. It does not answer one.
This paper proposes a novel integration framework called DREAM (Drop In, Recount, Enter, Amplify, Merge) designed to engage non-verbal, embodied, and imaginal aspects of psilocybin experience that resist verbal description. The framework is hypothesis-generating and operationalized as a testable clinical heuristic; two pilot studies are described as currently in progress but no results are reported.
Journal article. Patients with cancer receiving psilocybin therapy; clinical observations and illustrations from Bosnak's work and completed psilocybin trial participants. Intervention: DREAM protocol (participatory-imaginal processing framework) for post-psilocybin integration.
Proposed DREAM protocol operationalizes participatory-imaginal processing as a structured clinical heuristic for integration Authors hypothesize that direct engagement of embodied, imaginal register without verbal translation may help patients re-access and consolidate salient psychedelic experiences Two pilot studies in progress designed to assess feasibility, tolerability, and preliminary therapeutic relevance
Two pilot studies in progress designed to assess feasibility, tolerability, and preliminary therapeutic relevance
This framework is not yet evidence-based and should not inform clinical practice until the ongoing pilot studies are completed and reported. Clinicians interested in non-verbal integration approaches may consider the theoretical rationale as a basis for future investigation.
This is a conceptual framework paper proposing a novel integration approach for psychedelic therapy with no empirical results reported; pilot studies are described as ongoing but not completed.
As stated by the source record.
This framework is not yet evidence-based and should not inform clinical practice until the ongoing pilot studies are completed and reported. Clinicians interested in non-verbal integration approaches may consider the theoretical rationale as a basis for future investigation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Psilocybin therapy in patients with cancer commonly produces vivid embodied and imaginal experiences that resist verbal description, yet most current integration approaches rely primarily on cognitive and verbal processing. We hypothesize that an approach to integration that directly engages this embodied register, without requiring translation into a verbal narrative, will enable patients to re-access salient aspects of their psychedelic experience and consolidate them into a durable, re-enterable touchstone. We call this mode of processing participatory-imaginal processing. Drawing on Embodied Imagination, predictive processing models, and clinical observations from psilocybin therapy, we describe how participatory-imaginal processing can be invoked during integration sessions, how it provides an opportunity to revisit somatic, affective, and imaginal material from the psychedelic experience, and the way it can function as a hypothesis-generating therapeutic framework. Our method is called the DREAM protocol (Drop In, Recount, Enter, Amplify, Merge), which we designed as a structured clinical heuristic that operationalizes our approach in a form that can be taught and evaluated for feasibility and fidelity. We hypothesize that using DREAM to activate a participatory-imaginal mode of processing in integration may help patients re-engage somatically salient aspects of their psychedelic experience and identify embodied touchstones that remain accessible long afterward. We illustrate the framework using clinical material from Bosnak’s work and spontaneous reports from participants in completed psilocybin trials. Two pilot studies currently in progress are designed to assess the feasibility, tolerability, and preliminary therapeutic relevance of this approach in the immediate post-psilocybin period.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.